GlassScriptPhysician profile
Susan M Wang
NPI 1598880031
$88,111.24
in general payments reported to CMS, 2019-2025
56 companies · $3,151 in 2025
The $3,151 reported for 2025 was more than what 84% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $18K · 2021: $21K · 2022: $18K · 2023: $3,909 · 2024: $3,012 · 2025: $3,151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,795 · Education: $218 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,795.17 |
| Education | $218.26 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $55,945.54 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $8,747.48 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $8,212.01 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $2,164.48 | 2019-2025 | Evenity, Prolia, Prolia |
| Astrazeneca Pharmaceuticals LP | $2,139.41 | 2019-2025 | Farxiga, Breztri |
| Valeritas, INC. | $840.81 | 2019 | |
| Currax Pharmaceuticals LLC | $808.15 | 2019-2025 | Contrave, Nexletol, Nexlizet |
| Sanofi-Aventis U.S. LLC | $734.49 | 2019-2025 | |
| Abbott Laboratories | $700.43 | 2020-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $633.81 | 2019-2023 | Segluromet, Steglujan, Steglatro |
| Insulet Corporation | $586.88 | 2019-2025 | Omnipod |
| Amneal Pharmaceuticals LLC | $538.31 | 2019-2025 | Unithroid |
| Bayer Healthcare Pharmaceuticals INC. | $521.13 | 2021-2025 | |
| Amarin Pharma, INC. | $515.05 | 2019-2023 | |
| Abbvie INC. | $489.47 | 2019-2025 | Synthroid |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.